论文部分内容阅读
目的:评价抗耐甲氧西林金黄色葡萄球菌(MRSA)药物万古霉素和利奈唑胺在临床的应用情况。方法:对本院2008年1月～2010年9月万古霉素(含去甲万古霉素)和利奈唑胺的相关数据进行统计、分析。结果:万古霉素和利奈唑胺在本院有23个科室应用。骨科是抗MRSA药物用量最多的科室,其次为神经外科和呼吸科。2008～2010年万古霉素用量基本呈波动性增长;利奈唑胺片和注射剂均稳步增长;去甲万古霉素的用量变化不大。结论:本院万古霉素和利奈唑胺的应用基本合理,目前仍以万古霉素为主,可适当加强利奈唑胺的探索性临床研究,从而减轻万古霉素的用药压力。
Objective: To evaluate the clinical application of vancomycin and linezolid against methicillin-resistant Staphylococcus aureus (MRSA). Methods: The data of vancomycin (including norvancomycin) and linezolid in our hospital from January 2008 to September 2010 were statistically analyzed. Results: Vancomycin and linezolid were applied in 23 departments of our hospital. Orthopedics was the department with the most anti-MRSA drug usage, followed by neurosurgery and respiratory department. The amount of vancomycin increased basically from 2008 to 2010, linezolid tablets and injections increased steadily, and the amount of norvancomycin changed little. CONCLUSION: Our hospital vancomycin and linezolid are basically rational, and vancomycin is still the main factor in this hospital. The exploratory clinical trial of linezolid can be appropriately strengthened to relieve the pressure of vancomycin.